Immunicum AB: Invitation to Immunicum's Full-Year 2021 Review and Pipeline and Strategy Outlook Held as a Hybrid Event on February 17, 2022
Keep reading
Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021